WO2009040590A1 - Complex product with advanced assimilation efficacy for humans and its utilization - Google Patents

Complex product with advanced assimilation efficacy for humans and its utilization Download PDF

Info

Publication number
WO2009040590A1
WO2009040590A1 PCT/HU2007/000088 HU2007000088W WO2009040590A1 WO 2009040590 A1 WO2009040590 A1 WO 2009040590A1 HU 2007000088 W HU2007000088 W HU 2007000088W WO 2009040590 A1 WO2009040590 A1 WO 2009040590A1
Authority
WO
WIPO (PCT)
Prior art keywords
product
assimilation
vitamin
efficacy
complex product
Prior art date
Application number
PCT/HU2007/000088
Other languages
French (fr)
Inventor
Tibor Ficsur
László Szakacs
Original Assignee
Tibor Ficsur
Szakacs Laszlo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tibor Ficsur, Szakacs Laszlo filed Critical Tibor Ficsur
Priority to PCT/HU2007/000088 priority Critical patent/WO2009040590A1/en
Priority to BRPI0722045-6A priority patent/BRPI0722045A2/en
Priority to CA2700727A priority patent/CA2700727A1/en
Priority to EA201070401A priority patent/EA201070401A1/en
Priority to AU2007359463A priority patent/AU2007359463A1/en
Priority to EP07824980A priority patent/EP2209390A1/en
Priority to JP2010526377A priority patent/JP2010540510A/en
Priority to AP2010005243A priority patent/AP2010005243A0/en
Priority to CN2007801016274A priority patent/CN102098930A/en
Publication of WO2009040590A1 publication Critical patent/WO2009040590A1/en
Priority to NO20100595A priority patent/NO20100595L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C381/00—Compounds containing carbon and sulfur and having functional groups not covered by groups C07C301/00 - C07C337/00
    • C07C381/12—Sulfonium compounds
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/52—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C07C229/54—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C229/60—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring with amino and carboxyl groups bound in meta- or para- positions

Definitions

  • the aim of the inventon is to improve the assimilation of food that has become insufficient due to ageing as well as the harmful multiple effects caused during the process of natural ageing.
  • the objective of our invention is to develop and implement the simplest possible procedure that is feasible with ease.
  • the product in accordance with the innovation, consists of water-soluble methyl-methionine sulphonium iodide and paraaminobenzoic acid as well as fat-soluble carboxyl-uracil along with a unique emulsion system belonging to the latter to make it water-soluble without limitation.
  • the invention uses poliethoxy castor oil (ChremophorR EL, BASF) degraded during the metabolism and dimethyl-sulfoxide, thus making the use of the product of the invention possible for humans.
  • poliethoxy castor oil ChophorR EL, BASF
  • This product is assimilated in the form of water-soluble substance through the intestines, and contains no digestive and other enzymes.
  • Patent number P0700175 (applied for by ACHENTY S.A.: / UY) we can manufacture a water-soluble product for humans that is capable of restoring the reduced efficacy of food assimilation caused by various reasons.
  • Water-solubility was achieved with the highest success by the innovation for this specific occasion through a mixture of 15-43 mg of dimethyl-sulfoxide and 70-350 mg of poliethoxy castor oil.
  • this product plays an active role in reparing defficiencies of DNA as well.
  • the dimethyl-sulfoxide is famous for its successful penetration carrying various organic molecules through the dermis, and since it is generated during intermediate-metabolism, its utilization is obvious.
  • iodine is very important for the organism that considerably improves metabolism, which is especially necessary in our case.
  • the new complex iodide under certain circumstances - that are determined by the actual 'redox-potential ' or electro-motor power of various compounds or compound groups existing in the environment of this new complex - is capable of oxidising and reducing, thus it can restore positive or negative fluctuations in the potential of cell walls / cell membranes, caused by various harmful effects, that eventually result in reduced or fully terminated assimilation of foods.
  • This phenomenon is similar but not identical to the so-called 'dissipative ' systems, known to colloid chemists and physio-chemists, such as the mixture of cerium-sulphate, kalium- bromate, malonic acid and sulphur acid, in which the oxidisation status of the mixture changes in time and space within different time windows.
  • Another advantage of our innovation is that there is no specific order for mixing / deluting the above mentioned ingredients.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nutrition Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

For the manufacturing of a complex product with advanced assimilation efficacy, including methyl-methionine sulphonium, carboxyl-uracil, paraaminobenzoic acid, dimethyl-sulfoxide and poliethoxy castor oil, and its utilization.

Description

Complex Product with Advanced Assimilation Efficacy for Humans and its Utilization
We created our invention with the aim of restoring the appropriate level of food supply that has become reduced or insufficient due to viral-, bacterial-, fungal infections, harmful environmental emissions causing, amongst others, pollen-, and dust allergies, along with radiation-, and chemotherapy treatments, surgeries, UV-, X-ray and radioactive rays.
Also, the aim of the inventon is to improve the assimilation of food that has become insufficient due to ageing as well as the harmful multiple effects caused during the process of natural ageing.
In order for us to achieve these goals, the objective of our invention is to develop and implement the simplest possible procedure that is feasible with ease.
The product, in accordance with the innovation, consists of water-soluble methyl-methionine sulphonium iodide and paraaminobenzoic acid as well as fat-soluble carboxyl-uracil along with a unique emulsion system belonging to the latter to make it water-soluble without limitation.
To produce this emulsion, the invention uses poliethoxy castor oil (ChremophorR EL, BASF) degraded during the metabolism and dimethyl-sulfoxide, thus making the use of the product of the invention possible for humans.
This product is assimilated in the form of water-soluble substance through the intestines, and contains no digestive and other enzymes.
Considering the achievements of state-of-the-art technologies, no publication questioning the novelty of our procedure has been found in the literature.
Although the complex product with vitamins and minerals manufactured for animals under the Patent number of HU 224 444 contains methyl-methionine sulphonium chloride and kalium iodide, ad L: they are only used as components in the food, ad 2.: the advantages of the proper use of these two components are not recognised.
Moreover, the emulsion system of the complex product varies too.
Using our method protected by Patent number P0700175 (applied for by ACHENTY S.A.: / UY) we can manufacture a water-soluble product for humans that is capable of restoring the reduced efficacy of food assimilation caused by various reasons.
However, this result is achieved using an emulsion system including all the necessary vitamins, amino acids, minerals and micro elements known to be fundamental, that is completely different from our patented procedure presented hereby.
In order for us to achieve our goals, and above all, we need to know the reasons that cause reduced assimilation of food, which eventually can be partially or fully stopped, in terminal phase. Science undoubtedly has already proved that reduced or insufficient assimilation of food and destroyed assimilation dermises are to blame on the so-called fr ' ee radicals ' that are generated both by metabolites, toxins of viruses, bacteria and fungi, and by harmful environmental emissions causing, amongst others, pollen-, and dust allergies along with radiation-, and chemotherapy treatments, surgeries, UV-, X-ray and radioactive rays.
Similarly, unhealthy nutrition habits or dietary rules, NO2-NO3 content of food along with medicines, antibiotics causing harm to the wall of intestines and destroying the natural flora of intestines will also multiply the number of free radicals.
For the implementation of the innovation, it undoubtedly was of decisive importance for us to recognise that, first of all, we had to clarify the essence of these 'harmful effects ' to be able then to restore the normal functioning of the assimilation dermises of the organism.
The essence of free radicals ' was also clarified as being one of all different forms containing one electron-deficit oxygen.
This made it clear for us that, in order for us to achieve the goal of our innovation, we had to develop a product that could get food temporarily into the human organism through - and with the help of- its oxidiser-reductor system, called 'redox '.
First, we had to construct this so-called 'redox ' system, day-by-day, using the above mentioned building components in a way that the quantity and proportion of them match the fundamental requirements of a starving organism.
We must emphasize this fact, since now it is not replenishing special foods, but supplying the organism with basic foods using our product, stating at the same time that, using this specific product manufactured during our research and development work, we are capable of restoring the normal level of food assimilation with the highest possible speed and efficacy.
During the research and development phase, we found the following composition to be the best at restoring reduced or nearly terminal food assimilation:
A mixture of daily dosage of 30-150 mg of Methyl-methionine sulphonium chloride, 0.20-3.15 mg ofkalium-iodide, 11-56 mg of paraaminobenzoic acid and 6.5-31.0 mg of carboxyl-uracil, transformed in a proper way into water-soluble phase.
Water-solubility was achieved with the highest success by the innovation for this specific occasion through a mixture of 15-43 mg of dimethyl-sulfoxide and 70-350 mg of poliethoxy castor oil.
The direct and indirect anti-oxidant effects of paraaminobenzoic acid along with methyl- methionine sulphonium chloride are well known and so is the anti-microbial effect of paraaminobenzoic acid.
It is known that the carboxyl-uracil remarkably improves the assimilation of minerals, primarily that of magnesium from intestines.
According to the latest research, but mainly theoratical considerations, this product plays an active role in reparing defficiencies of DNA as well. The dimethyl-sulfoxide is famous for its successful penetration carrying various organic molecules through the dermis, and since it is generated during intermediate-metabolism, its utilization is obvious.
However, it took us by surprise, as it was unexpected, that it was only the dimethyl-sulfoxide that was able to mix carboxyl-uracil with the emulsion system of our innovation.
Adding iodine to the product manufactured during the implemenation phase seems surprising and question was raised as to how such a strong oxidising substance can be mixed with a system that is basically anti-oxidant.
However, on the other hand, iodine is very important for the organism that considerably improves metabolism, which is especially necessary in our case.
In the course of manufacturing the patented product we have come to a surprising result of unexpected when mixing the non-organic iodine, that is kalium iodide, used for this product, with methyl-methionine sulphonium chloride in a separate procedure, during the manufacturing process.
This unexpected surprising result, the new complex iodide, under certain circumstances - that are determined by the actual 'redox-potential ' or electro-motor power of various compounds or compound groups existing in the environment of this new complex - is capable of oxidising and reducing, thus it can restore positive or negative fluctuations in the potential of cell walls / cell membranes, caused by various harmful effects, that eventually result in reduced or fully terminated assimilation of foods.
This phenomenon is similar but not identical to the so-called 'dissipative ' systems, known to colloid chemists and physio-chemists, such as the mixture of cerium-sulphate, kalium- bromate, malonic acid and sulphur acid, in which the oxidisation status of the mixture changes in time and space within different time windows.
The discovery of this phenomenon is of paramount importance because any kind of positive or negative of change in the 'redox-potential' of given cell-organelles within the cells of living organisms spells out the beginning of harmful effects including all sorts of diseases and processes of ageing as well.
These changes will also bring about fatal deterioration, and, eventually, a complete loss of efficacy of assimilation through the alimentary canal.
This is what makes it clear how crucial it is that, through the development of our innovative product, we can provide a system that contains anti-oxidants the functioning of which will be secured by a 'redox-molecule ' that stabilises the system in a complex formula as detailed above.
This stabilising effect can be detected 'in vitro ' as well. The paramount importance of the 'redox-status ' in the cells of living organism is justified by the discovery that won Mr. Otto Warburg the Nobel-prize for proving the anaerob - that is reduction - processes that can be detected in cells infected with cancer.
In the course of the manufacturing the product we created a molecule, including methyl- methionine iodide with paraaminobenzoic acid and carboxyl-uracil, that becomes water- soluble by adding poliethoxy castor oil and dimethyl-sulf oxide, that brings us to a product that is capable of restoring reduced or terminated assimilation of foods, on its own.
The manufacturing process of our innovative product consists of four steps:
• The production process of the emulsion system to make the fat-soluble ingredients water-soluble - mixing the dilution — during which we take 6.5-31 mg of carboxyl- uracil with 15-43 mg of dimethyl-sulfoxide and mix them with 0-350 mg of Chremophor® EL (BASF) heated to a temperature of 65 degrees Centigrade. Following the 7 -minute mixing, the material that has cooled out is homogenous and ready for packing.
• The production process of 'redox-complex ' using methyl-methionine sulphonium chloride and kalium-iodide, - mixing the powder -, during which 30-105 mg of methyl-methionine sulphonium chloride is slowly and thoroughly mixed with 0.20- 3.15mg of kalium-iodide for 15 minutes.
• Mixing the 'redox-complex', that was produced first, with 11-56 mg of paraaminobenzoic acid,- mixing the powder -,
• Packaging the liquid and powder separately into capsules, but our innovative product makes it possible to have the complex in water-soluble, single-phase format.
The versatility of our innovative product also makes it possible for us - in certain cases, when, or example, feeding through infusion-tube is temporarily necessary - to add to the water- soluble format the daily dosages of vitamins, crucial amino acids, unsaturated fatty acids, macro-, and micro elements, such as:
110-180 mg of calcium-lactate, 75-110 mg of vitamin C, 60-100 mg of glutamic acid, 30-45 mg L-asparagic acid, 28-35 mg of L-arginine, 27-33 mg of L-Ornihtine, 15-30 mg of L- Cysteine, 3.6-21.5 mg of L-Carnitine, 35-50 mg of vitamin Bl, 38-45 mg of vitamin B2, 28-60 mg of vitamin B6, 38-80 mg of Niacin amid, 15-40 mg of Ca d-pantothenate, 13-45 mg ofm- Inositol, 5-20 mg of Folic acid, 6-18 mg of Rutin, 0.15-0.40 mg of d-Biotin, 0.15-0.24 mg of Natrium selenite, 0.21-0.65 mg of Natrium molybdate, 21-62 mg ofFell-lactate, 0.03-0.1 mg of Cobalt-chloride, 25.4-42.0 mg of Zinc chloride, 10-30 mg ofMangane chloride, 20-80 mg ofθmega3 oil, 11-20 mg of vitamin E acetate, 4-21.2 mg ofβ karotin, 70-210 mg of soy- lecithin, 900-3600 IU of vitamin A palmitate and 150-240 IU of vitamin D3.
Another advantage of our innovation, in this case, is that there is no specific order for mixing / deluting the above mentioned ingredients.
Through the following, but not exclusive, exhibits, we 'd like to introduce our innovation, bearing in mind that they have no limiting effect on the scope of protection of the Patent: Exhibit 1.
For this purpose, we manufactured 1, 000 daily dosages of our innovative product (which daily dosage we found sufficient for a 70 kg Chron-patient to restore his digestive system which is partly or fully unable to assimilate food) according to the following method:
We mixed 20 gr of carboxyl-uracil and 18 gr of dimethyl-sulfoxide with 210 gr ofChremophorR EL for 7 minutes and stirred steadily in a mixing bowl.
We mixed 102 gr of methyl-methionine sulphonium chloride and 0.30 gr of kalium iodide by stirring for 15 minutes in a laboratory homogeniser, then homogenised this substance once again with an additional 15 gr ofparaaminobenzoic acid. We halved both the liquid and the powder,
We packed one of the half quantities, that is 500 dosages, one-by-one, into capsules for voluntary Chron-patients,
- We deluted the other half of the quantities with water and mixed in order for us to assess the reaction of the substance during delution with water, should it be needed,
Both the emulsion-system and the powdered fraction of the product we have manufactured, following the delution with water separately or in one, is free from sediment, even in case of very thin delution.
Exhibit 2.
Some of the Chron-patients were given dosages of our innovative product in capsules
(four men and three women; one of the men had had 6 cm of his small intestine removed by surgery.
All patients were prescribed to take one liquid and one powder capsule every day.
After 5 days, all the seven patients reported improved appetite, after 2 weeks all of them have put on weights of 1.5-2.3 kg.
Interestingly, the patient that underwent surgery showed the largest rate of growth in weight.
This exhibit proves that the product, manufactured in accordance with the innovaton, itself is capable of restoring terminated or reduced assimilation of food for humans.

Claims

The complex product according to any of claims:
L, The complex product with advanced efficacy in assimilation for humans according to any of claims, that the product contains methyl-methionine sulphonium iodide carboxyl-uracil, paraaminobenzoic acid, dimethyl-sulfoxide and poliethoxy castor oil.
2., The complex product with advanced efficacy in assimilation for humans according to any of claims, that the methyl-methionine sulphonium iodide is made out of kalium-iodide and methyl-methionin sulphonium chloride, in a separate procedure.
3., The complex product with advanced efficacy in assimilation for humans according to any of claims, that, the product, in accordance with Point 2. of claims, is made out of 30-105 weight unit of methyl-methionine sulphonium chloride, 0.20-3.15 weight unit of kalium- iodide, 11-56 weight unit of paraaminobenzoic acid, 5.5-31 weight unit of carboxyl-uracil, 15-43 weight unit of dimethyl-sulfoxide and 70-350 weight unit of poliethoxy castor oil, or the multiple of these weight units.
4., The complex product with advanced efficacy in assimilation for humans according to any of claims, that, the product in accordance with Point L, of claims, is used for the manufacturing of the product that restores to normal the reduced or terminated capability of assimilation of foods in intestines.
5., The complex product with advanced efficacy in assimilation for humans according to any of claims, that the product, in accordance with Point L, of claims, in certain cases, can be mixed with:
>
110-180 mg of calcium-lactate, 75-110 mg of vitamin C, 60-100 mg of glutamic acid, 30-45 mg L-asparagic acid, 28-35 mg of L-arginine, 27-33 mg of L-Ornitin, 15-30 mg L-Cysteine, 3.6-21.5 mg of L-Carnitine, 35-50 mg of vitamin Bl, 38-45 mg of vitamin B2, 28-60 mg of vitamin B6, 38-80 mg of Niacin amid, 15-40 mg of Ca d-pantothenate, 13-45 mg of m- Inositol, 5-20 mg of Folic acid, 6-18 mg of Rutin, 0.15-0.40 mg of d-Biotin, 0.15-0.24 mg of Natrium selenite, 0.21-0.65 mg of Natrium molybdate, 21-62 mg of Fell-lactate, 0.03-0.1 mg of Cobalt-chloride, 25.4-42.0 mg of Zinc chloride, 10-30 mg ofMangane chloride, 20-80 mg of Omega3 oil, 11-20 mg of vitamin E acetate, 4-21.2 mg of β karotin, 70-210 mg of soy- lecithin, 900-3600 IU of vitamin A palmitate and 150-240 IU of vitamin D3.
PCT/HU2007/000088 2007-09-26 2007-09-26 Complex product with advanced assimilation efficacy for humans and its utilization WO2009040590A1 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
PCT/HU2007/000088 WO2009040590A1 (en) 2007-09-26 2007-09-26 Complex product with advanced assimilation efficacy for humans and its utilization
BRPI0722045-6A BRPI0722045A2 (en) 2007-09-26 2007-09-26 ADVANCED ASSIMILATION EFFICIENCY COMPLEX PRODUCT FOR HUMANS AND ITS USE
CA2700727A CA2700727A1 (en) 2007-09-26 2007-09-26 Complex product with advanced assimilation efficacy for humans and its utilization
EA201070401A EA201070401A1 (en) 2007-09-26 2007-09-26 COMPLEX PRODUCT WITH IMPROVED EFFICIENCY OF DEVELOPMENT FOR PEOPLE AND ITS APPLICATION
AU2007359463A AU2007359463A1 (en) 2007-09-26 2007-09-26 Complex product with advanced assimilation efficacy for humans and its utilization
EP07824980A EP2209390A1 (en) 2007-09-26 2007-09-26 Complex product with advanced assimilation efficacy for humans and its utilization
JP2010526377A JP2010540510A (en) 2007-09-26 2007-09-26 Complex products with high anabolic efficacy for humans and uses thereof
AP2010005243A AP2010005243A0 (en) 2007-09-26 2007-09-26 Complex product with advanced assimilation efficacy for humans and its utilization
CN2007801016274A CN102098930A (en) 2007-09-26 2007-09-26 Complex product with advanced assimilation efficacy for humans and its utilization
NO20100595A NO20100595L (en) 2007-09-26 2010-04-23 Composite product with good absorption effect for humans, and its use

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/HU2007/000088 WO2009040590A1 (en) 2007-09-26 2007-09-26 Complex product with advanced assimilation efficacy for humans and its utilization

Publications (1)

Publication Number Publication Date
WO2009040590A1 true WO2009040590A1 (en) 2009-04-02

Family

ID=40510777

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/HU2007/000088 WO2009040590A1 (en) 2007-09-26 2007-09-26 Complex product with advanced assimilation efficacy for humans and its utilization

Country Status (10)

Country Link
EP (1) EP2209390A1 (en)
JP (1) JP2010540510A (en)
CN (1) CN102098930A (en)
AP (1) AP2010005243A0 (en)
AU (1) AU2007359463A1 (en)
BR (1) BRPI0722045A2 (en)
CA (1) CA2700727A1 (en)
EA (1) EA201070401A1 (en)
NO (1) NO20100595L (en)
WO (1) WO2009040590A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102802616A (en) * 2009-04-22 2012-11-28 圣地亚哥-德孔波斯特拉大学 Polyarginine Nanocapsules

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU224444B1 (en) * 2002-11-28 2005-09-28 László Szakács Liquid, water-dilutable composition for animals with complete vitamin and mineral substance content and process for its production
RU2277354C2 (en) * 2000-08-22 2006-06-10 Сосьете Де Продюи Нестле С.А. Food composition, method for production and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2277354C2 (en) * 2000-08-22 2006-06-10 Сосьете Де Продюи Нестле С.А. Food composition, method for production and uses thereof
HU224444B1 (en) * 2002-11-28 2005-09-28 László Szakács Liquid, water-dilutable composition for animals with complete vitamin and mineral substance content and process for its production

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
"Sera - mineral krasoty", 1 September 2004 (2004-09-01), XP008133147, Retrieved from the Internet <URL:http:l/eyoung.narod.ru/msm.htm> [retrieved on 20080428] *
DATABASE MEDLINE [online] "false", XP008138493, Database accession no. pmid:1298157 *
HEGEDUS M. ET AL: "Bioavailability of methionine-hydroxy-analog free acid and S-methyl-methionine in the growing rat", ACTA VETERIAN HUNGARICA, vol. 40, no. 3, 1992 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102802616A (en) * 2009-04-22 2012-11-28 圣地亚哥-德孔波斯特拉大学 Polyarginine Nanocapsules

Also Published As

Publication number Publication date
EA201070401A1 (en) 2010-10-29
JP2010540510A (en) 2010-12-24
BRPI0722045A2 (en) 2014-03-25
CN102098930A (en) 2011-06-15
AU2007359463A1 (en) 2009-04-02
NO20100595L (en) 2010-06-25
AP2010005243A0 (en) 2010-04-30
CA2700727A1 (en) 2009-04-02
EP2209390A1 (en) 2010-07-28

Similar Documents

Publication Publication Date Title
Li et al. Therapeutic vesicular nanoreactors with tumor‐specific activation and self‐destruction for synergistic tumor ablation
US20150190443A1 (en) Broccoli Based Nutritional Supplements
CN103598192B (en) A kind of bactericidal composition containing tetramycin and Zhongshengmycin
Paśko et al. Effect of amaranth seeds in diet on oxidative status in plasma and selected tissues of high fructose-fed rats
CN105580807A (en) A mixed preparation of eugenol and garlicin
CN104304797B (en) A kind of manufacturing process of livestock and poultry B B-complex nano-emulsion
EP2779842B1 (en) Composition for protection against cell-damaging effects
NO180473B (en) Process for the preparation of an enteral pharmaceutical preparation for the treatment of ectoparasitic fish diseases
EP2209390A1 (en) Complex product with advanced assimilation efficacy for humans and its utilization
CN105284828A (en) Copper abietate and zinc thiazole-containing bactericidal composition
CN105340913A (en) Sterilization composition containing benziothiazolinone and kasugamycin
CN105748489A (en) A composite vitamin ADE oil injection for veterinary use and a preparing method thereof
CN104839433A (en) New cinnamaldehyde microemulsion bacteriostatic agent for feed
CN105052950A (en) Bactericidal composition containing tetramycin and ethylicin
CN102342523A (en) Preparation method for selenized carrageenan water-in-oil emulsion, and product and application of selenized carrageenan water-in-oil emulsion
Karthishwaran et al. Assessment of the antioxidant potential of Pergularia daemia (Forsk.) extract in vitro and in vivo experiments on hamster buccal pouch carcinogenesis
CN105340915A (en) Sterilization composition containing benziothiazolinone and Xinjunan acetate
RU2229286C2 (en) Ibuprofen ointment prepared on polyethylene oxide base and eliciting anti-inflammatory effect
CN105394039A (en) Bactericidal composition containing oxine-copper and ethylicin
CN102846489B (en) Polyhexamethyleneguanidine hydrochloride iodine medicine bath liquid and preparation method thereof
CN104585216B (en) A kind of miticide composition of containing pyriminostrobin
CN108042558B (en) Abamectin preparation for aquaculture and preparation method thereof
CN105010361A (en) Sterilization composition containing tetramycin and boscalid
RU2154470C2 (en) Complex medicinal preparation for treatment of rabbits with eumeriosis
RU2557773C1 (en) Composition for lipids oxidation stabilisation

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200780101627.4

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07824980

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2700727

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2010526377

Country of ref document: JP

Ref document number: MX/A/2010/003343

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2010030496

Country of ref document: EG

WWE Wipo information: entry into national phase

Ref document number: 2007359463

Country of ref document: AU

Ref document number: 584858

Country of ref document: NZ

Ref document number: 2007824980

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: DZP2010000235

Country of ref document: DZ

WWE Wipo information: entry into national phase

Ref document number: 11772

Country of ref document: GE

Ref document number: 10048907

Country of ref document: CO

Ref document number: 201011394

Country of ref document: CR

Ref document number: 848/MUMNP/2010

Country of ref document: IN

Ref document number: 1020107009134

Country of ref document: KR

Ref document number: 201070401

Country of ref document: EA

Ref document number: CR2010-011394

Country of ref document: CR

WWE Wipo information: entry into national phase

Ref document number: PI 2010001355

Country of ref document: MY

ENP Entry into the national phase

Ref document number: 2007359463

Country of ref document: AU

Date of ref document: 20070926

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: PI0722045

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20100326